Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ramucirumab · 1 trial · 2 indications
Overall survival (OS) is defined as the time from date of randomization until death from any cause.
| Arm | Type | Description |
|---|---|---|
| Trastuzumab deruxtecan | EXPERIMENTAL | Participants who will be randomized to receive a 6.4 mg/kg intravenous (IV) dose of trastuzumab deruxtecan once every 3 weeks on Day 1 of each 21-day cycle. |
| Ramucirumab + paclitaxel | ACTIVE_COMPARATOR | Participants who will be randomized to receive a 8 mg/kg IV dose of ramucirumab on Days 1 and 15 in combination with 80 mg/m\^2 IV dose of paclitaxel on Days 1, 8, and 15 of a 28-day cycle. |
| Name | Type | Description |
|---|---|---|
| Trastuzumab deruxtecan | DRUG | 6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle |
| Ramucirumab | DRUG | 8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle |
| Paclitaxel | DRUG | 80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle |
Inclusion Criteria: * Adults (according to local regulation) and able to provide informed consent for study participation. * Pathologically documented gastric and GEJ adenocarcinoma that has been previously treated in the metastatic setting (unresectable, locally advanced, or metastatic disease). *...
Ramucirumab is an investigational oncology drug being studied for gastric cancer and adenocarcinoma, specifically in HER2-positive gastric cancer or gastro-esophageal junction adenocarcinoma after progression on or after a trastuzumab-containing regimen. It is being evaluated in combination with paclitaxel in a Phase 3 clinical trial.
Ramucirumab targets KDR, also known as vascular endothelial growth factor receptor 2 (VEGFR-2), and acts as an inhibitor of this receptor. By inhibiting KDR, it is designed to interfere with tumor angiogenesis, which is the process by which tumors develop new blood vessels to support their growth.
Ramucirumab is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's efficacy and safety in the treatment of gastric cancer and adenocarcinoma.
Ramucirumab is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness for the treatment of gastric cancer and adenocarcinoma.
Ramucirumab is being studied in the clinical trial NCT04704934, titled "Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)." This Phase 3 trial is active but not recruiting, with an enrollment of 490 participants.
Ramucirumab is also known as Ramucirumab plus paclitaxel, which refers to the combination therapy being evaluated in clinical trials. The drug is being studied in combination with paclitaxel for the treatment of gastric cancer and adenocarcinoma, as part of the investigational regimen.